NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free VINC Stock Alerts $5.51 -0.55 (-9.08%) (As of 09:45 AM ET) Add Compare Share Share Today's Range$5.51▼$6.0850-Day Range$1.07▼$8.0652-Week Range$0.61▼$9.37Volume62,690 shsAverage Volume1.09 million shsMarket Capitalization$117.80 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vincerx Pharma alerts: Email Address Vincerx Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside17.5% Downside$5.00 Price TargetShort InterestBearish6.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.99) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector858th out of 939 stocksPharmaceutical Preparations Industry397th out of 436 stocks 1.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Vincerx Pharma has a forecasted downside of 17.5% from its current price of $6.06.Amount of Analyst CoverageVincerx Pharma has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.42% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently increased by 95.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 3.1 News and Social Media Coverage News SentimentVincerx Pharma has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vincerx Pharma this week, compared to 0 articles on an average week.Search Interest17 people have searched for VINC on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.MarketBeat Follows10 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($1.99) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Vincerx Pharma Stock (NASDAQ:VINC)Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More VINC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VINC Stock News HeadlinesMarch 19, 2024 | edition.cnn.comVincerx Pharma IncMarch 12, 2024 | benzinga.comWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 28, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug PipelineMarch 5, 2024 | globenewswire.comVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024March 5, 2024 | finance.yahoo.comVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekFebruary 22, 2024 | morningstar.comVincerx Pharma Inc Ordinary Shares VINCFebruary 22, 2024 | benzinga.comVincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and DatesMarch 28, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.January 10, 2024 | msn.comVincerx Pharma stock rises on positive efficacy data from lymphoma therapyJanuary 8, 2024 | msn.comWhy Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?January 8, 2024 | marketwatch.comVincerx Pharma Shares Surge Following Early Results for Relapsed, Refractory LymphomaJanuary 8, 2024 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaJanuary 7, 2024 | finance.yahoo.comVincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in LymphomaNovember 14, 2023 | msn.comVincerx Pharma GAAP EPS of -$0.46November 14, 2023 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 13, 2023 | finance.yahoo.comNew to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business NetworkSeptember 19, 2023 | finance.yahoo.comVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023September 14, 2023 | finance.yahoo.comVincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943September 8, 2023 | benzinga.comDelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MMAugust 23, 2023 | msn.comFDA approves Vincerx’s IND application for trial of VIP943August 23, 2023 | benzinga.comCancer Antibody Drug Conjugates Market Size Clinical Trials InsightAugust 23, 2023 | proactiveinvestors.comVincerx Pharma receives FDA clearance for early-stage leukemia trialAugust 22, 2023 | marketwatch.comVincerx Pharma Shares Jump 8% Premarket After FDA Clearance for Clinical TrialAugust 10, 2023 | finance.yahoo.comVincerx Pharma (NASDAQ:VINC) Will Have To Spend Its Cash WiselyAugust 7, 2023 | finance.yahoo.comVincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateMay 23, 2023 | finance.yahoo.comRichter's Syndrome Pipeline Insight Report 2023: Featuring Secura Bio, Genmab, Genentech, Acerta Pharma & Vincerx PharmaSee More Headlines Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside-17.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-160.15% Return on Assets-116.11% Debt Debt-to-Equity RatioN/A Current Ratio2.58 Quick Ratio2.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book2.69Miscellaneous Outstanding Shares21,381,000Free Float16,977,000Market Cap$129.57 million OptionableNot Optionable Beta1.03 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 59)Founder, Chairman & CEO Comp: $609.84kDr. Raquel E. Izumi Ph.D. (Age 54)Founder, President, COO, Secretary & Director Comp: $551.66kMr. Alexander A. Seelenberger M.B.A. (Age 45)Chief Financial Officer Comp: $458.03kMr. Tom C. Thomas J.D. (Age 65)Founder, General Counsel & Chief Legal Officer Comp: $444.14kDr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardDr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Gabriela JairalaSr Executive Director of Investor Relations & Corporate CommunicationsMs. Karen QuarfordVice President of Quality Operations & ComplianceMs. Melissa Merrick SPHRSenior Director of People & Culture and Head of Human ResourceDr. Beatrix Stelte-Ludwig Ph.D.Executive Chief Development OfficerMore ExecutivesKey CompetitorsOramed PharmaceuticalsNASDAQ:ORMPCyteir TherapeuticsNASDAQ:CYTTAdageneNASDAQ:ADAGIO BiotechNASDAQ:IOBTLantern PharmaNASDAQ:LTRNView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Sold 353,270 shares on 3/1/2024Ownership: 7.997%Citadel Advisors LLCBought 28,530 shares on 2/15/2024Ownership: 0.923%Goldman Sachs Group Inc.Sold 353,270 shares on 2/13/2024Ownership: 7.997%Alexander A SeelenbergerBought 10,500 shares on 8/11/2023Total: $9,975.00 ($0.95/share)Ahmed Md HamdyBought 16,900 shares on 8/9/2023Total: $16,055.00 ($0.95/share)View All Insider TransactionsView All Institutional Transactions VINC Stock Analysis - Frequently Asked Questions Should I buy or sell Vincerx Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks. What is Vincerx Pharma's stock price target for 2024? 1 Wall Street analysts have issued 1-year target prices for Vincerx Pharma's shares. Their VINC share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 17.5%. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts. How have VINC shares performed in 2024? Vincerx Pharma's stock was trading at $1.18 at the beginning of 2024. Since then, VINC stock has increased by 413.6% and is now trading at $6.06. View the best growth stocks for 2024 here. Are investors shorting Vincerx Pharma? Vincerx Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 863,700 shares, an increase of 95.2% from the February 29th total of 442,400 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.4% of the shares of the stock are sold short. View Vincerx Pharma's Short Interest. When is Vincerx Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VINC earnings forecast. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) announced its earnings results on Thursday, August, 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.18. Who are Vincerx Pharma's major shareholders? Vincerx Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (8.00%), Goldman Sachs Group Inc. (8.00%) and Citadel Advisors LLC (0.92%). Insiders that own company stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Christopher P Lowe, Laura I Bushnell, Raquel E Izumi and Tom C Thomas. View institutional ownership trends. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VINC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.